作者：王秋雁

单位：文昌市人民医院消化内科，海南 文昌 571300

Authors:  WANG Qiuyan

Unit:  Department of Gastroenterology, Wenchang people's Hospital, Wenchang 571300, Hainan, China

摘要：

目的  分析血清1,25-二羟维生素D3水平与胰腺癌的相关性。方法  将2016年1月至2017年12月我院收治的132例胰腺癌患者纳入研究对象,另将同期到我院体检的80例健康体检者作为对照组,采集两组晨起空腹外周静脉血,应用酶联免疫吸附法检测血清1,25-二羟维生素D3水平,比较两组血清1,25-二羟维生素D3水平,并分析血清1,25-二羟维生素D3水平与胰腺癌患者临床病理特征及预后的相关性。结果  胰腺癌组的血清1,25-二羟维生素D3水平[(28.62±8.23)pg/mL]明显低于健康对照组[(43.71±5.42)pg/mL](P<0.05)。血清1,25-二羟维生素D3水平与胰腺癌患者的分化程度、TNM分期、淋巴结转移有关(P<0.05),而与患者的性别、年龄、病理分型、肿瘤部位、肿瘤直径及有无黄疸无明显关系(P>0.05)。缺乏组(≤20μg/L)与正常组(>20μg/L)的无进展生存期分别为5个月和10个月,95%CI分别为3.1-7.9个月和7.6-13.24个月(P<0.05)。缺乏组(≤20μg/L)与正常组(>20μg/L)的总生存期分别为7个月和13个月,95%CI分别为4.7-9.3个月和10.2-17.6个月(P<0.05)。结论  血清1,25-二羟维生素D3水平降低可能与胰腺癌的发生、进展及不良预后有关,提高1,25-二羟维生素D3水平可能有助于改善胰腺癌患者的预后。

关键词： 胰腺癌; 1,25-二羟维生素D3; 临床病理特征; 预后; 相关性

Abstract：

Objective  To analyze the correlation between serum 1,25- dihydroxyvitamin D3 level and pancreatic cancer. Methods  132 patients with pancreatic cancer admitted to our hospital from January 2016 to December 2017 were enrolled in the study, and 80 healthy people who were examined in our hospital at the same time were selected as the control group. The serum levels of 1,25-dihydroxyvitamin D3 were measured by enzyme-linked immunosorbent assay (ELISA). The serum levels of 1,25-dihydroxyvitamin D3 were compared between the two groups. The correlation between serum levels of 1,25-dihydroxyvitamin D3 and clinicopathological features and prognosis of pancreatic cancer patients was analyzed. Results The serum levels of 1,25-dihydroxyvitamin D3 in pancreatic cancer group [(28.62 (8.23) pg/mL)] were significantly lower than those in healthy control group [(43.71 (5.42) pg/mL] (P<0.05). The serum levels of 1,25-dihydroxyvitamin D3 were correlated with the degree of differentiation, TNM stage and lymph node metastasis (P<0.05), but not with sex, age, pathological type, tumor location, tumor diameter and jaundice (P>0.05). The progression-free survival time of deficiency group (<20 g/L) and normal group (>20 g/L) were 5 months and 10 months, 95% CI was 3.1-7.9 months and 7.6-13.24 months respectively (P<0.05). The total survival time of deficiency group (<20 g/L) and normal group (>20 g/L) were 7 months and 13 months respectively, 95% CI was 4.7-9.3 months and 10.2-17.6 months respectively (P<0.05). Conclusion  The decrease of serum 1,25-dihydroxyvitamin D3 level may be related to the occurrence, progression and poor prognosis of pancreatic cancer. Increasing the level of 1,25-dihydroxyvitamin D3 may help to improve the prognosis of patients with pancreatic cancer.

Key Words:  Pancreatic cancer; 1,25- dihydroxyvitamin D3; Clinicopathological features; Prognosis; Correlation